Now with ~1,000 children and adolescents with multi-inflammatory syndrome in children (MIS-C), it can be considered a new disease. Today new @NEJM reports and an editorial on its status. I've made a summary of some key points to start

Here is the USA report of 186 patients with locations of diagnoses, organ involvement and labs
https://www.nejm.org/doi/full/10.1056/NEJMoa2021680?query=featured_home

The outstanding editorial, by Michael Levin
https://www.nejm.org/doi/full/10.1056/NEJMe2023158
a report from New York State to follow later

Here is the New York State report today of 99 patients
https://www.nejm.org/doi/full/10.1056/NEJMoa2021756?query=featured_coronavirus
with clusters of manifestations (the high % skin, GI, cardiac, neurologic, KD=Kawasaki's), therapy used, and associated diagnoses

So there's a paradox of the vast majority of children and adolescents that are spared from either susceptibility or adverse outcomes; yet a rare subgroup with MIS-C. A commentary in today's @TheLancetRheum explores the immunologic considerations
https://www.thelancet.com/action/showPdf?pii=S2665-9913%2820%2930212-5

Today the MISC-C report from France and accompanying editorial @LancetChildAdol
https://www.thelancet.com/action/showPdf?pii=S2352-4642%2820%2930175-9
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30207-8/fulltext
consistent with distinct phenotype, 2 week lag and other points in the US reports this week